Key Findings
Driven by the increasingly stringent European Union In Vitro Diagnostic Regulation (IVDR) and the escalating frequency of global infectious disease outbreaks, China’s Point-of-Care Testing (POCT) industry is rapidly entering a ‘golden era’ of globalization. The EU IVDR has introduced unified and rigorous standards for the market placement and surveillance of in vitro diagnostic medical devices, significantly elevating the entry barriers for POCT products into global markets. This regulatory tightening has incentivized Chinese enterprises to prioritize quality and technological innovation, presenting a substantial opportunity to bolster their international competitiveness.
Technical / Clinical Details
The EU IVDR imposes stricter requirements compared to its predecessor, the In Vitro Diagnostic Directive (MDD), particularly concerning product clinical validation, Unique Device Identification (UDI) registration within EUDAMED, and the submission of comprehensive technical documentation. Meeting these demands necessitates that POCT products adhere to high performance standards and rigorous quality control processes. Chinese POCT manufacturers, traditionally recognized for their cost-effective solutions, are now enhancing product reliability and performance through their compliance efforts with IVDR. Specifically, in areas such as infectious disease diagnostic kits, blood glucose meters, and cardiac marker detectors, Chinese products leverage the inherent strengths of POCT—on-site operability, rapid result delivery, and minimal infrastructure requirements—to address diagnostic needs in resource-constrained regions and urgent care settings.
Background & Context
The global infectious disease pandemics have underscored the critical importance of rapid and accessible diagnostic tools, with POCT playing an indispensable role in enabling immediate decision-making and curbing disease spread when central laboratory processing faced delays. Furthermore, the IVDR aims to standardize quality and safety benchmarks internationally, preventing the influx of unreliable products and enhancing consumer protection. Supported by robust government backing, abundant R&D resources, and extensive manufacturing capabilities, China’s POCT industry has adapted to these international standards and is progressively developing products that often exceed them. This strategic evolution is transforming China from merely a manufacturing hub into a global innovator of diagnostic solutions.
Strategic Significance & Outlook
The globalization of China’s POCT industry is poised to fundamentally reshape the landscape of diagnostics in the global healthcare market. In emerging economies, reliable and cost-effective POCT products are expected to play a crucial role in improving basic healthcare services. Simultaneously, in developed markets, the application scope of POCT is expanding further into areas such as home self-diagnosis, telemedicine, and continuous monitoring of chronic diseases. Through the integration of cutting-edge technologies like AI, IoT, and nanotechnology, Chinese POCT products are set to offer more intelligent and personalized diagnostic solutions. This ‘golden era’ signifies a pivotal phase for China to establish a leading role in the global POCT market, driving innovation and expanding access to essential diagnostics worldwide.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments